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Cervical cancer is the second leading cause of death from cancer in
women worldwide (Pont￿n et al, 1995). Advances in surgical tech-
niques, radiation therapy and the use of adjuvant chemotherapy
have resulted in little improvement in the stage-by-stage cure rates
of carcinoma of the cervix during the past 25 years (Kapp and
Giaccia, 1996). Radiotherapy is the most important non-surgical
treatment for cervical carcinoma. The tumour stage is still believed
to be the most important determinant of prognosis in cervical
carcinoma, and tumour size has also been used as a marker of
response to radiotherapy and prognosis for many years (Virostek
et al, 1996).
A better understanding of the molecular biology and radio-
biology of cervical cancer will likely lead to the identification of
new therapeutic interventions. Apoptosis plays an important role
in the cytotoxic effects of radiation therapy (Harima et al, 1998)
and chemotherapy (Lowe et al, 1994). The activation of the
tumour suppressor gene (TSG) p53 is associated with induction of
apoptosis (Lowe et al, 1993). The biological behaviour of cervical
cancer is determined by the nature of defects or mutations in key
genes such as p53. However, in contrast to the situation in many
other human tumours, p53 mutations are only rarely detected in
cervical cancers (Chang et al, 1995).
The inactivation or deletion of multiple TSGs, which otherwise
regulate the normal cellular growth and suppression of abnormal
cell proliferation, is recognized to be one of the major mechanisms
of tumorigenesis. Mutations or deletions in a TSG are frequently
accompanied by loss of the remaining allele, leading to homozy-
gous inactivation of the gene (Marshall, 1991). Several studies
have shown that loss of heterozygosity (LOH) at specific chromo-
somal sites is frequently associated with the development of
various cancers, e.g. 3p14—p23 in small-cell lung carcinoma,
1p32—p36 in neuroblastoma, 13q14 in retinoblastoma, 5p21 in
familiar adenomatous polyposis and 11p13—p15 in Wilms￿ tumour
(Marshall, 1991). Although they have been relatively few, cyto-
genetic studies of cervical carcinoma have revealed frequent non-
random chromosomal changes (Atkin et al, 1990). Studies of LOH
in cervical carcinoma have also reported a high frequency of
allelic deletions affecting 3p (Yokota et al, 1989; Jones et al, 1992;
Kohno et al, 1993), 5p (Mitra et al, 1995), 6p (Mullokandov et al,
1996) and 11p (Srivatsan et al, 1991). LOH on 17p of cervical
carcinoma has also been reported (Mullokandov et al, 1996; Jones
et al, 1994; Mitra et al, 1994). Structural abnormalities of the short
arm and loss of chromosome 17 have been reported to confer resis-
tance to chemotherapy in patients with head and neck cancer (Li X
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However, the importance of genetic alterations (GA) on chromo-
some 17p in the response of cervical cancer to radiotherapy
remains unknown.
In this study, we evaluated the incidence of LOH and MI at
17p13 in the DNA of patients with cervical cancer, and assessed
their impact on the outcome of radiotherapy.
MATERIALS AND METHODS
Patient characteristics
Between January 1995 and April 1998, 50 patients with histologi-
cally proven carcinoma of the uterine cervix (four stage Ib, five
stage IIb, one stage IIIa, 30 stage IIIb, six stage IVa, four stage
IVb) were treated with definitive radiotherapy at Kansai Medical
University. The follow-up for the surviving patients ranged from 1
to 43 months, with a mean of 22.5 months. The mean patient age
was 67.3 years (range 47—86 years). The primary tumours ranged
in diameter from 1 to 11.9 cm (mean 6 cm), as measured by
magnetic resonance imaging (MRI). Typical staging included a
history, a physical examination, routine blood counts, a blood
chemistry profile, a chest radiograph, an intravenous urogram,
colonoscopy and computerized tomography (CT) and/or MRI.
Patients were staged jointly by the radiation oncology and gynae-
cologic oncology staff according to the International Federation of
Gynecology and Obstetrics (FIGO) classification (FIGO Annual
Report, 1979), with modifications. The tumours consisted of 45
squamous cell carcinomas and five adenocarcinomas. No patient
received chemotherapy prior to the radiotherapy. Each of the
patients signed a consent form approved by the Kansai Medical
University Review Board describing the experimental nature of
the treatment.
Irradiation techniques and doses
All patients entered in the protocol were treated with external
pelvic radiation therapy using 6-MV high-energy linear accelera-
tors. A total of 30.6 Gy was provided to the whole pelvis, plus an
additional dose to the parametria with central shielding to
complete 52.2 Gy, along with 192Ir high-dose-rate intracavitary
brachytherapy. Radiation was delivered to the tumour in fractions
of 1.8 Gy daily, 5 days per week. The dose of 192Ir brachytherapy,
administered at a high dose rate, was 30 Gy to point A (point A
being 2 cm lateral to the central canal of the uterus and 2 cm up
from the mucous membrane of the lateral fornix, in the axis of the
uterus) (ICRU Report 38, 1985), given as 7.5 Gy per session once
per week.
Detection and typing of HPV
Tumour samples were obtained from the 50 patients by punch
biopsy prior to radiotherapy. Punch biopsies were taken from two
to four different parts of each tumour and frozen immediately at
—80°C. Genomic DNA was extracted from each tumour according
to standard protocols (Bauer et al, 1992).
Tumour DNA was amplified by the polymerase chain reaction
(PCR) with primers specific for human papillomavirus (HPV) 16,
18, 33 and 58 E6, as previously described (Yoshikawa et al, 1990).
The PCR was carried out for 40 cycles at 95°C for 1.5 min, 48°C
for 1.5 min and 70°C for 2 min, using a BioGene PHC-1 system
(Techne, Cambridge, UK).
Investigation of p53 status
Mutations of the p53 gene were identified by a single-strand
conformation polymorphism (SSCP) analysis and DNA
sequencing of tumour biopsies as previously described (Chen et al,
1993), using primers flanking the evolutionarily conserved regions
of the gene from exon 5 to exon 8. Each exon was amplified
separately using sense and antisense oligonucleotide primers
flanking the exon as shown: exon 5, sense 5¢-TTCCTCTTCCT-
GCAGTACTC-3¢ and antisense 5¢-GCCCCAGCTGCTCAC-
CATCG-3¢; exon 6, sense 5¢-CACTGATTGCTCTTAGGTCTG-3¢
and antisense 5¢-AGTTGCAAACCAGACCTCAG-3¢; exon 7,
sense 5¢-CCAAGGCGCACTGGCCTC-3¢ and antisense 5¢-
GCGGCAAGCAGAGGCTGG-3¢; exon 8, sense 5¢-CCTATCCT-
GAGTAGTGGTAATC-3¢, and antisense 5¢-GTCCTGCTTG-
CTTACCTCGC-3¢. All mutations were confirmed by sequencing
or an SSCP analysis of a second independent PCR reaction. The
products of this reaction were subcloned into TA vector (TA
Cloning kit, Invitrogen). A mixture of at least 50 subclones was
used as the template for DNA sequencing using a T7 sequencing
kit (Boehringer Mannheim), visualized by exposure to Kodak
XAR film with an intensifying screen at —80°C.
Investigation of LOH and MI on 17p13.1
Regions of the genomic DNA extracted from the blood and tumour
of each patient were amplified. PCR was utilized to detect the
presence of LOH and MI on chromosome 17p with the three
microsatellite markers D17S796, D17S1353 and D17S1881
(17p13.1). The PCR of each region was cycled 35 times at 94°C
for 1 min, 55°C for 1 min, and 72°C for 1 min using each fluores-
cent set as previously described (Dib et al, 1996). The PCR prod-
ucts loaded on a 6% polyacrylamide gel were analysed by
automatic sequencing (ALFred, Pharmacia; Uppsala, Sweden).
Allelic losses were scored as decreases in intensity of one allele
relative to the other as determined from a comparison of tumour
and normal DNAs. MI was scored by comparing the electro-
phoretic pattern of the microsatellite markers amplified from the
paired DNA specimen. The shift was indicated by either an addi-
tion or deletion of one or more repeat units resulting in the genera-
tion of novel microsatellite alleles. The analysis in the LOH- and
MI-positive cases was repeated at least twice, and the results were
highly reproducible.
Statistical methods
Survival was measured as the time (days) from the date of the start
of radiotherapy. The relationship between the presence/absence of
genetic alterations on chromosome 17p13.1 and the radioresponse
was analysed with Fisher￿s exact test. The tumour size data were
analysed with a two-tailed Student￿s t-test. Actuarial survival was
estimated by the Kaplan—Meier (1958) method, and differences in
survival were analysed by the Breslow-Gehan-Wilcoxon test
(Gehan, 1965). The statistical analyses were performed using Stata
4.0 Software (Stata Statistical Software: Release 4.0, Stata Corp.,
College Station, TX, USA). P-values below 0.05 were considered
significant.
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RESULTS
Overall, 82% of the patients (41 of 50) had advanced disease. At
present, 33 patients (66%) are alive and well (NED, no evidence of
disease), five patients are alive with cancer disease (AWD) and 12
patients (24%) have died from recurrent disease (CD, cancer-
caused death). In the patients with AWD and CD, eight patients
have had a local failure, two have had distant metastases (lung in
one patient, para-aortic lymph nodes in one), and seven have had
both local failure and distant metastases (multiple metastases, six;
lung, one).
Relationships among stage, tumour size, response and
patient outcome
There was a correlation between the stage of disease and the
patients￿ response. All nine patients with stage I or II showed
NED. In contrast, 17 of the 41 patients with advanced-stage cancer
(i.e. stage III or IV) showed AWD or CD (P = 0.02). The tumour
sizes were 3.8 ± 2 cm in the stage I—II patients, 5.9 ± 1.9 cm in
stage III, and 8.4 ± 2.2 cm in stage IV. The statistical analysis
using the two-tailed Student￿s t-test revealed significant differ-
ences in tumour size between stage I—II and stage III (P = 0.006),
and stage I—II versus stage IV (P = 0.0002). The tumour size
increased with the stage of disease. At the time point at which the
tumour size of the NED patients was 5 ± 2 cm, it had increased to
7.8 ± 2.7 cm in the AWD patients, and to 8 ± 1.5 cm in the CD
patients. The difference in size was significant between the NED
and AWD groups (P = 0.008), and NED versus CD groups (P =
0.00003, two-tailed Student￿s t-test). The mean tumour diameter of
all patients was 6 ± 2.4 cm. We divided the patients into those with
tumours smaller than 6 cm in diameter (n = 26) and those with
tumours equal to or greater than 6 cm in diameter (n = 24). There
was a significant difference in survival between these groups
(P = 0.0002, Breslow—Gehan—Wilcoxon test); the former group
survived significantly longer than the latter group.
The presence of HPV infection, stage, tumour size and
outcome
HPV 16, 18, 33 or 58 genomes were detected by PCR in 19
patients (38%): in one stage I, four stage II, 11 stage III and three
stage IV patients. The tumour size was 6.2 ± 2.5 cm in the HPV-
positive tumours versus 5.9 ± 2.4 cm in the HPV-negative
tumours. Of the HPV-positive patients, 13 have NED, four are
AWD and two suffered CD. Of the HPV-negative patients, 20 have
NED, one is AWD and ten suffered CD. Thus, there were no
significant correlations between the tumour size (two-tailed
Student￿s  t-test), response (Fisher￿s exact test) or survival (P =
0.12, Breslow—Gehan—Wilcoxon test) and HPV status.
Relationships between p53 status and stage, tumour
size and outcome
p53 mutations were detected by SSCP analysis in six patients
(12%): in five stage III patients and one stage IV patient. We
observed p53 mutations in codon 245, changing GGC to AGC,
causing the substitution of serine for glysine; in codon 146, TGG
to TAG, resulting in the substitution of a stop codon for trypto-
phane; in codon 189, GCC to GTC, causing the substitution of
valine for alanine; and in codon 286, GAA to CAA, resulting in
the substitution of glutamine for glutamic acid; and in codon 285,
GAG to AAG, resulting in the substitution of lysine for glutamic
acid; and in codon 213, CGA to TGA, resulting in the substitution
of stop codon for arginine.
The tumour size was 8.2 ± 2.9 cm in the mutant p53 tumours
versus 5.7 ± 2.2 cm in the wild-type p53 tumours; there was corre-
lation between tumour size and p53 status (P = 0.02, two-tailed
Student￿s t-test). Of the mutant p53 patients, three have NED, one
is AWD and two suffered CD. Of the wild-type p53 patients, 30
have NED, four are AWD and ten suffered CD. There was no
significant relationship between the NED group or AWD/CD
group and p53 status (Fisher￿s exact test). There was no significant
Table 1 Clinicopathological characteristics of 50 patients with cervical
carcinomas according to presence/absence of genetic alterations (GA) on
chromosome 17p13.1
GA-positive GA-negative P
tumours (n = 19) tumours (n = 31)
Age (years)
Mean 68.1 66.9 NSa
SD 10.6 8.5
Stage
I0 4 N S b
II 1 4
III 10 21
IV 8 2
Histological type
Squamous cell carcinoma 17 28 NSb
Adenocarcinoma 2 3
Tumour size (cm)
Mean 7.1 5.3 0.009a
SD 2.5 2.1
p53 status
Wild-type 13 31 0.002b
Mutant-type 6 0
HPV infection
Positive 6 13 NSb
Negative 13 18
aTwo-tailed Student’s t-test; bFisher’s exact test.
Table 2 Relationship between response to radiotherapy in all 50 patients:
those with a tumour size smaller than 6 cm, greater than 6 cm and
presence/absence of genetic alteration (GA) on chromosome 17p13
GA-positive tumours GA-negative tumours P
(n = 19) (n = 31)
All cases (n = 50)
NED 8 25 0.007
AWD/CD 11 6
< 6 cm (n = 26)
NED 6 18 NS
AWD/CD 0 2
³ 6 cm (n = 24)
NED 2 7 0.02
AWD/CD 11 4
NED, no evidence of disease; AWD, alive with disease; CD, cancer death.
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difference in survival between the wild-type p53 patients and
mutant  p53 patients (P = 0.23, Breslow—Gehan—Wilcoxon test).
Relationships between GA on chromosome 17p13.1
and stage, tumour size and outcome
Nineteen of the 50 tumours displayed GA on 17p13.1 (38%), 16
(32%) showed LOH and three (6%) showed MI (Figure 1). The
tumour size was 7.1 ± 2.5 cm in the GA-positive tumours, signifi-
cantly larger than 5.3 ± 2.1 cm in the 31 GA-negative tumours
(P = 0.009, two-tailed Student￿s t-test). LOH on 17p13.1 was seen
in one stage II case, nine stage III, and six stage IV patients. MI on
17p13.1 was seen in one stage III patient and two stage IV
patients. There was no correlation between the GA status and age,
stage, histological type, or HPV infection. LOH was observed in
all cases with mutant p53, but in none of the patients with MI.
Thus, p53 status was significantly related with the GA status (P =
0.002, Fisher￿s exact test, Table 1).
As shown in Table 2, of the 19 GA-positive patients, eight have
NED (42.1%), four are AWD and seven showed CD. Of the 31
GA-negative patients, 25 have NED (80.6%), one is AWD and
five showed CD. When we divided the patients into an NED group
and an AWD/CD group, there was significant relationship between
each of these groups and GA (P = 0.007, Fisher￿s exact test). We
also evaluated the relationship between the two tumour-size
groups and GA. In the group of patients with tumours smaller than
6 cm, all six of the GA-positive patients have NED, while 18 of
the GA-negative patients have NED and two are AWD/CD. One of
the patients with AWD had para-aortic lymph nodes metastases
and another, with CD, had lung metastasis, although complete
local control had been achieved in both patients. Thus, there was
no correlation between GA and radiotherapy response in the
tumours smaller than 6 cm. In the group of patients with tumours
‡ 6 cm, two of the 13 GA-positive patients have NED and 11 are
AWD/CD. Of the GA-negative patients, seven have NED and four
are AWD/CD. Thus, there was a significant relationship between
GA and the radiotherapy response in the tumours 6 cm or greater
(P = 0.02, two-tailed Student￿s t-test). In addition, among all
patients, the GA-negative patients survived significantly longer
compared to the GA-positive patients (P = 0.026, Breslow—
Gehan—Wilcoxon test, Figure 2).
DISCUSSION
The reported frequencies of LOH on 17p of cervical carcinoma
vary considerably (between 15% and 35%) (Jones et al, 1994;
Mitra et al, 1994; Mullokandov et al, 1996). In the present study,
we investigated the correlation between response to radiotherapy
and the incidence of LOH and MI at chromosome 17p in both
tumour tissue specimens and blood of 50 patients with cervical
carcinoma. In this study, LOH occurred in 32% of the tumours (16
of 50) and MI was revealed in 6% (three of 50). The patients with
GA-positive tumours had significantly poorer responses (P = 0.02)
and shorter survival (P = 0.026) compared to the GA-negative
patients. These findings are consistent with results of studies of
resistance to chemotherapy in patients with LOH on 17p in head
and neck cancer (Li X et al, 1994) and in neuroblastoma (Caron et
al, 1995).
Here, we report three patients with cervical cancer who showed
MI in tumours on 17p13.1. Germline mutations in mismatch repair
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Figure 1 Representative results of absence of genetic alteration (GA) (A), presence of loss of heterozygosity (LOH) (B), and presence of microsatellite
instability (MI) (C) with the microsatellite marker D17S796 (17p13.1). The region was amplified of the genomic DNA extracted from blood (black line) and
tumours (red line) of patients. The microsatellite alleles are represented by two peaks (heterozygotes). LOH (B) and MI (C) are indicated by red arrowheads
Figure 2 Survival of patients with respect to presence/absence of genetic
alteration (GA) on chromosome 17p13 using the Kaplan–Meier method and
analysed by Breslow–Gehan–Wilcoxon test. The 31 GA-negative patients
survived significantly longer compared to the 19 GA-positive patients
(P = 0.026)
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genes (hMSH2, hMLH1, hPMS1 and hPMS2) (Fishel et al, 1993;
Leach et al, 1993; Bronner et al, 1994; Nicolaides et al, 1994;
Papadopoulos et al, 1994) cause a subset of familial colorectal
cancers, termed hereditary non-polyposis colorectal cancer
(HNPCC) (Lynch et al, 1993). As a consequence of such muta-
tions, errors arising during DNA replication are less efficiently
corrected. However, the relationship between MI and cervical
carcinomas remains unclear. With the exception of one report
(Mitra et al, 1995), there is no evidence of MI in cervical carci-
nomas. In the report by Mitra et al (1995), LOH and MI were
studied only in the 5p14-ter region, and replication error-type
alterations were found in six (13%) of 46 invasive carcinomas, two
(40%) of five cases of carcinoma in situ (CIS) and three (21%) of
14 precancerous lesions. In our study, we found MI in the 17p13
region in three cervical cancer patients, one at stage III, two at
stage IVb. None of these three tumours were infected HPV or
harboured mutant-p53. We suspect that cervical tumours with
genetic instability might have other alterations related to mismatch
repair system genes, such as hMLH1 and hMSH2.
The importance of the p53 gene in clinical oncology has been
reviewed (Chang et al, 1995). A poor response of human malig-
nancies to different therapies is often associated with mutations of
the p53 gene, such as in breast cancer (Aas et al, 1996) and colon
cancer (Ahnen et al, 1998). In contrast to the situation in many
other human tumours, p53 mutations are only rarely detected in
cervical cancers (Chang et al, 1995). In the present study also, only
six of the 50 patients (12%) were found to have mutations in the
p53 gene, as evaluated by an SSCP analysis of genomic DNA. The
six tumours with mutant p53 had G:C to A:T mutations. These
data are in agreement with a report on the high frequency of G:C to
A:T mutations in cervical carcinoma (Park et al, 1994).
Most cervical carcinomas have been shown to contain HPV
DNA sequences, including the high risk-HPV 16 and HPV 18
types (zur Hausen and de Villier, 1994). The binding of high risk-
HPV types E6 viral protein to p53 protein has been shown to result
in a rapid ubiquitin-dependent proteolytic degradation of p53
(Scheffner et al, 1990). Therefore, the presence of high-risk forms
of HPV is believed to result in a loss of the p53-mediated control
of cell growth (Butz et al, 1995). In general, the presence of high-
risk HPV in tumour cells is thought to be associated with a poor
prognosis in cervical cancer treated with radical hysterectomy
(Burger, 1996). It has been shown, however, that HPV-positive
cancer cells may preserve the p53 protein in its functional form
(Butz et al, 1995). This observation may partially explain discrep-
ancies in the results of studies examining the correlation between
the presence of various types of HPV DNA in tumours and treat-
ment outcome in cervical cancer (King et al, 1989; Higgins et al,
1991). In the case of cervical carcinoma, there is an obvious need
to study the effects of HPV infection on intrinsic tumour cell
radiosensitivity (Kapp and Giaccia, 1996). However, the literature
on differences in prognosis between HPV-positive and HPV-nega-
tive tumours is incomplete (Kristensen et al, 1996; Burger et al,
1996). No correlations were found between HPV infection and
treatment outcome in our study.
E6 type-specific PCR was more sensitive than L1 consensus
PCR (Iwasaka et al, 1996), therefore we evaluated HPV status
using type-specific E6 primers. In this study, 38% of the patients
(19 of 50) were HPV-positive. There are three explanations for this
low rate of HPV-positive tumours. At first, Matsumoto et al (1997)
reported that HPV-positive tumours were detected in 49% of
cervical cancers obtained from Japanese women. In the second,
Kawana (1995) reported that HPV-DNA was detected more
frequently in the cases of cervical dysplasia than among those of
cervical cancer in Japan. Due to the high rate (82%) of advanced-
stage patients in this study, the low rate of HPV-positive tumours
might have occurred. In the third, the mean age of patients was
67.3 years (range 47—86 years) in our study. At the same time, the
prevalence of HPV in western Europe and USA is generally less
than 10% at 40 years of age or older (Schiffman et al, 1992).
In this study, tumour size was found to be the most important
determinant of response to radiotherapy and prognosis for cervical
carcinoma, which is in agreement with previous reports (Virostek
et al, 1996). There was no correlation between the response and
GA in the tumours smaller than 6 cm. In contrast, among the
patients with tumours ‡ 6 cm, the response of the patients with
GA-positive tumours was significantly poorer than that of the GA-
negative patients. The results of this study suggest that GAs on 17p
are important predictors of outcome following radiation treatment
in patients with bulky cervical carcinomas. The higher incidence
of GA in tumours or greater than 6 cm may explain, at least in part,
the poor prognosis of this category of patients.
The analysis of genetic instability in patients with advanced
cervical carcinomas might help to clarify further the mechanisms
of the rapid progression and poor treatment response in some indi-
viduals. In turn, such analysis will contribute essential knowledge
for the development of new strategies for cancer gene therapy.
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